Expert Opinion On Drug Safety
Scope & Guideline
Fostering Scholarly Dialogue on Drug Safety
Introduction
Aims and Scopes
- Pharmacovigilance and Drug Safety Analysis:
The journal emphasizes the importance of pharmacovigilance, aiming to monitor, assess, and understand adverse drug reactions and safety signals associated with various medications. - Clinical Safety Evaluations:
It provides comprehensive evaluations of drug safety through systematic reviews, meta-analyses, and real-world studies, offering insights into the efficacy and safety of drugs across multiple therapeutic areas. - Risk-Benefit Assessments:
The journal focuses on the balance between the therapeutic benefits of drugs and their potential risks, providing guidance for clinicians in making informed treatment decisions. - Emerging Drug Safety Concerns:
It addresses new and emerging safety concerns related to drugs, particularly in the context of novel therapies and changing treatment paradigms. - Real-World Evidence Integration:
The journal integrates real-world evidence to enhance understanding of drug safety in diverse populations and clinical settings, ensuring that findings are applicable to everyday medical practice.
Trending and Emerging
- Real-World Evidence and Data Mining:
There is a growing emphasis on utilizing real-world evidence and advanced data mining techniques to uncover adverse drug reactions and safety signals, reflecting a shift towards more data-driven approaches in pharmacovigilance. - Machine Learning and Artificial Intelligence in Drug Safety:
The integration of machine learning and AI technologies in pharmacovigilance is trending, with studies focusing on their potential to improve signal detection and risk assessment in drug safety. - Patient-Centric Pharmacovigilance:
An emerging focus on incorporating patient perspectives, experiences, and reported outcomes into drug safety evaluations is evident, aiming to enhance the relevance and applicability of findings. - Safety of Novel Therapeutics and Biologics:
Research is increasingly directed towards the safety profiles of novel therapeutics, including biologics and targeted therapies, particularly in oncology and immunology, reflecting the rapid advancement of these treatment modalities. - Long-Term Safety and Post-Marketing Surveillance:
There is a heightened interest in long-term safety studies and post-marketing surveillance, emphasizing the need to monitor drugs after they have been approved and widely prescribed.
Declining or Waning
- Traditional Pharmacovigilance Methods:
There is a noticeable decline in studies focusing solely on traditional pharmacovigilance methods, as the field shifts towards more innovative and technology-driven approaches such as machine learning and big data analytics. - Generalized Drug Safety Reviews:
The trend towards more specialized and targeted safety evaluations has led to a decrease in broad, generalized reviews of drug safety, which may have been more common in earlier publications. - Historical Drug Safety Studies:
Research focusing on historical data or older medications is becoming less prevalent, as the journal increasingly prioritizes contemporary drugs and therapies. - Single-Agent Safety Studies:
There is a waning interest in studies examining the safety of single-agent therapies, with a growing focus on combination therapies and polypharmacy, especially in complex patient populations. - Pharmacovigilance in Non-Pharmaceutical Contexts:
The journal has seen a reduction in articles addressing pharmacovigilance in non-pharmaceutical contexts, such as dietary supplements or herbal products, which were previously more common.
Similar Journals
Safety
Leading the way in safety research and knowledge sharing.Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.
INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE
Fostering a culture of safety in medicine.INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE, published by IOS Press, serves as an essential platform for advancing the understanding of risk and safety within the medical domain. With an ISSN of 0924-6479 and E-ISSN of 1878-6847, this journal has been dedicated to fostering critical discourse since its inception in 1990, reflecting a continuous commitment to the field through 2024. Positioned within the Q4 category in Health Policy and Q3 in Medicine (miscellaneous) and Public Health, Environmental and Occupational Health, the journal provides valuable insights, empirical research, and theoretical analyses that speak to the diverse challenges faced in medical safety and risk management. Although it operates under a subscription model, the journal remains a vital resource for researchers, healthcare professionals, and students alike, facilitating the exchange of innovative ideas and best practices in health risk assessment. With Scopus ranks indicating its role as a key contributor in its categories, the INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE continues to shape the landscape of medical safety and policy discussions around the globe.
BMC Pharmacology & Toxicology
Fostering collaboration in pharmacology and toxicology.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.
ANNALS OF PHARMACOTHERAPY
Unveiling the Future of Pharmacological ResearchANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Innovating research for safer medication practices.Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.
BRITISH JOURNAL OF PHARMACOLOGY
Exploring the frontiers of pharmacology and toxicology.British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.
DRUGS IN R&D
Shaping the future of pharmacology with impactful insights.DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Transforming clinical research into therapeutic excellence.JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Pioneering Discoveries in Biological and Pharmaceutical ResearchBIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.
DRUGS
Elevating Standards in Drug Research ExcellenceDRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.